Show simple item record

dc.contributor.authorZhou, Xin
dc.contributor.authorCai, Dongyan
dc.contributor.authorXiao, Shaoqing
dc.contributor.authorNing, Meng
dc.contributor.authorZhou, Renwu
dc.contributor.authorZhang, Shuo
dc.contributor.authorChen, Xiao
dc.contributor.authorOstrikov, Kostya
dc.contributor.authorDai, Xiaofeng
dc.date.accessioned2020-04-29T01:37:38Z
dc.date.available2020-04-29T01:37:38Z
dc.date.issued2020
dc.identifier.issn1837-9664
dc.identifier.doi10.7150/jca.38613
dc.identifier.urihttp://hdl.handle.net/10072/393478
dc.description.abstractBackground: With the anti-cancer efficacies of cold atmospheric plasma being increasingly recognized in vitro, a demand on creating an effective tool feasible for in vivo animal treatment has emerged. Methods: Through the use of co-axial needles with different calibers in diameter, we designed a novel in situ ejection source of cold atmospheric plasma, namely invivoPen, for animal experiments. It punches just a single pinhole that could considerably ease the complexity of operating with small animals such as mouse. Results: We showed that invivoPen could deliver similar efficacies as plasma activated medium with reduced cost in suppressing cell proliferation and migration as well as potentially boosting the viabilities of mice receiving invivoPen treatment. Blood test, renal and liver functionalities tests all suggest that physical plasma could effectively return tumor-carrying mice to the healthy state without harm to body conditions, and invivoPen slightly outweighs PAM in boosting animal immunity and reducing inflammation. Conclusion: Our study contributes to the community in providing a minimal invasive in situ plasma source, having partly explained the efficacies of cold atmospheric plasma in treating triple negative breast cancers, and proposing the potential synergies between physical plasma and conventional drugs for cancer treatment.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherIvyspring International Publisher
dc.relation.ispartofpagefrom2273
dc.relation.ispartofpageto2282
dc.relation.ispartofissue8
dc.relation.ispartofjournalJournal of Cancer
dc.relation.ispartofvolume11
dc.subject.fieldofresearchOncology and Carcinogenesis
dc.subject.fieldofresearchcode1112
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsOncology
dc.subject.keywordstriple negative breast cancer
dc.subject.keywordsplasma jet
dc.titleInvivoPen: A novel plasma source for in vivo cancer treatment
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationZhou, X; Cai, D; Xiao, S; Ning, M; Zhou, R; Zhang, S; Chen, X; Ostrikov, K; Dai, X, InvivoPen: A novel plasma source for in vivo cancer treatment, Journal of Cancer, 2020, 11 (8), pp. 2273-2282
dcterms.dateAccepted2020-01-04
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.date.updated2020-04-29T01:34:14Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
gro.hasfulltextFull Text
gro.griffith.authorOstrikov, Kostya (Ken)


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record